Literature DB >> 26884871

Clinico-pathological characteristics and prognostic factors of gastrointestinal stromal tumors among a Chinese population.

Jiehua Li1, Haitian Zhang1, Zhibai Chen1, Ka Su1.   

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common primary mesenchymal tumors of the digestive tract. GISTs include a group of heterogeneous tumors with different morphology, biologic behavior, and genetic characteristics, so their epidemiology, clinico-pathological features and prognosis is distinct in different countries. The objective of this study is to analyze clinico-pathological characteristics and prognostic factors of GISTs among Chinese population. We investigated 112 GIST patients were diagnosed between July 2008 and January 2013 at the First Affiliated Hospital of Guangxi Medical University. Histologic evaluation and immunohistochemistry analysis was performed on paraffin-embedded tissue from the 112 GISTs. Overall survival analysis was carried out using the Kaplan-Meier method and the log-rank test. Multivariate analysis was performed according to Cox's proportional hazards model. Three and 5-year OS rates were 71.4 and 58.6% respectively. Univariate analysis showed that the following factors were significant in predicting OS: tumor site, tumor size, metastasis, resection margin status, cell type, invasion of adjacent organ, invasion of smooth muscle, mitotic rate, P53 and adjuvant therapy with imatinib (P<0.05). Multivariate analysis showed that tumor size, metastasis, resection margin status, mitotic rate, P53 and adjuvant therapy with imatinib were independent prognostic factors associated with OS. This may aid in the prediction of clinical evolution and guide treatments in patients with GIST in China.

Entities:  

Keywords:  Gastrointestinal stromal tumor; clinical features; pathologic features; prognostic factors

Mesh:

Substances:

Year:  2015        PMID: 26884871      PMCID: PMC4730084     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  26 in total

1.  Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

Authors:  Martin D McCarter; Cristina R Antonescu; Karla V Ballman; Robert G Maki; Peter W T Pisters; George D Demetri; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Linda McCall; David M Ota; Ronald P DeMatteo
Journal:  J Am Coll Surg       Date:  2012-07       Impact factor: 6.113

2.  Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

Authors:  Markku Miettinen; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

Review 3.  Multiple non-metastatic gastrointestinal stromal tumors. Differential features.

Authors:  M Díaz-Delgado; A Hernández-Amate; M Sánchez-León; S Pereira-Gallardo; E Prieto-Sánchez; M Jiménez-Sáenz; R González-Cámpora
Journal:  Rev Esp Enferm Dig       Date:  2010-07       Impact factor: 2.086

4.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Authors:  Dian Wang; Qiang Zhang; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren; Burton L Eisenberg
Journal:  Ann Surg Oncol       Date:  2011-12-28       Impact factor: 5.344

Review 5.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

6.  Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

Authors:  Ann W Gramza; Christopher L Corless; Michael C Heinrich
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

Review 7.  Distinguishing gastrointestinal stromal tumors from their mimics: an update.

Authors:  Susan C Abraham
Journal:  Adv Anat Pathol       Date:  2007-05       Impact factor: 3.875

8.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

Authors:  Ronald P Dematteo; Jason S Gold; Lisa Saran; Mithat Gönen; Kui Hin Liau; Robert G Maki; Samuel Singer; Peter Besmer; Murray F Brennan; Cristina R Antonescu
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

Review 9.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authors:  George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; Robert G Maki; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
Journal:  J Natl Compr Canc Netw       Date:  2007-07       Impact factor: 11.908

10.  Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective.

Authors:  Ravindra S Date; Nicholas A Stylianides; Kishore G Pursnani; Jeremy B Ward; Muntzer M Mughal
Journal:  World J Surg Oncol       Date:  2008-07-18       Impact factor: 2.754

View more
  2 in total

1.  Prognostic value of fibrinogen and D-dimer-fibrinogen ratio in resectable gastrointestinal stromal tumors.

Authors:  Hua-Xia Cai; Xu-Qi Li; Shu-Feng Wang
Journal:  World J Gastroenterol       Date:  2018-11-28       Impact factor: 5.742

2.  Gastrointestinal stromal tumor: clinicopathological characteristics and pathologic prognostic analysis.

Authors:  Chayanit Jumniensuk; Mongkon Charoenpitakchai
Journal:  World J Surg Oncol       Date:  2018-12-03       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.